验证SONG-PKD疼痛量表:ADPKD疼痛核心结局测量工具
本研究在316名来自21个国家的成人ADPKD患者中在线验证SONG-PKD疼痛量表(含频率、严重度和生活参与影响3个条目,5点Likert量表)。结果显示该量表内部一致性高(Cronbach's α=0.94,95%CI 0.93-0.95),重测信度好(ICC=0.92,95%CI 0.90-0.94),与BPI-SF和VAS高度收敛(ρ=0.84),且能区分有无肾脏并发症史的患者(中位评分4.0 vs 0.0,P<0.001)。
要点
- SONG-PKD疼痛量表包含3个条目,评估疼痛频率、严重度和对生活参与的影响。
- 量表内部一致性(α=0.94)和重测信度(ICC=0.92)均高。
- 量表与BPI-SF和VAS收敛效度高(ρ=0.84),可区分有无并发症史患者。
核心结论
- SONG-PKD疼痛量表是一种简短、简单的测量工具,在成人ADPKD患者中显示出强有力的心理测量学特性。
研究设计与样本
- 研究纳入来自21个国家的316名成人ADPKD患者,在线完成人口学问卷、简要病史和4种疼痛测量,2天后重测疼痛测量。
主要发现
- SONG-PKD疼痛量表内部一致性Cronbach's α为0.94(95%CI 0.93-0.95),重测信度ICC为0.92(95%CI 0.90-0.94)。
- SONG-PKD疼痛量表与BPI-SF的收敛效度Spearman's ρ为0.84(95%CI 0.80-0.87),与VAS的ρ为0.84(95%CI 0.81-0.87)。
- 有肾脏并发症史患者的中位疼痛评分显著高于无并发症史患者(4.0 vs 0.0,P<0.001)。
临床怎么用
- SONG-PKD疼痛量表可作为一种简短的疼痛评估工具用于ADPKD患者的临床研究和实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pain is a critically important outcome in autosomal dominant polycystic kidney disease (ADPKD); however, it is infrequently and inconsistently reported in clinical trials. This study aimed to validate the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Pain measure, which includes 3 items related to pain (frequency, severity, and impact on life participation) measured on a 5-point Likert scale, in adults with ADPKD. METHODS: A total of 316 adults with ADPKD from 21 countries participated online. The median (interquartile range) age of participants was 56 (44-66) years, 219 (69%) were female, and 222 (70%) had a university degree or higher. Participants completed a demographic questionnaire, brief medical history, and 4 pain measures at baseline. The pain measures were readministered 2 days later. Internal consistency was evaluated with Cronbach's alpha. Test-retest reliability was assessed using intraclass correlation coefficient (ICC), and convergent validity was assessed using Spearman's rho. Known groups comparisons for patients with or without a history of kidney complications were performed using a Mann-Whitney rank sum test. RESULTS: The SONG-PKD Pain measure demonstrated high internal consistency (0.94, 95% confidence interval [CI]: 0.93-0.95) and test-retest reliability (0.92, 95% CI: 0.90-0.94). There was a high convergence of SONG-PKD Pain with the Brief Pain Inventory-Short Form (BPI-SF; 0.84, 95% CI: 0.80-0.87) and a visual analog scale (VAS; 0.84, 95% CI: 0.81-0.87). There was a significant difference in the median scores of patients with and without a history of complications (4.0 vs. 0.0, P < 0.001). CONCLUSION: SONG-PKD Pain instrument is a brief and simple measure that has demonstrated strong psychometric properties.
引用
- Cazzolli R, Ju A, Natale P, et al. Validating the SONG-PKD Pain Instrument, a Core Outcome Measure for Pain in ADPKD. Kidney Int Rep. 2024. PMID: 39990913. doi:10.1016/j.ekir.2024.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。